J2KBIO Past Earnings Performance
Past criteria checks 1/6
There is insufficient data on J2KBIO's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | n/a |
Return on equity | 26.9% |
Net Margin | 17.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How J2KBIO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 28,472 | 4,844 | 4,332 | 1,217 |
30 Sep 23 | 24,780 | 4,100 | 4,000 | 1,118 |
31 Mar 23 | 18,560 | 2,756 | 3,744 | 1,005 |
Quality Earnings: A420570 has a high level of non-cash earnings.
Growing Profit Margin: Insufficient data to determine if A420570's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A420570's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A420570's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: Insufficient data to determine if A420570's earnings growth over the past year exceeded the Biotechs industry average.
Return on Equity
High ROE: A420570's Return on Equity (26.9%) is considered high.